Latest Inhaler Stories

REDWOOD CITY, Calif., Aug. 30, 2011 /PRNewswire/ -- Pearl Therapeutics Inc. today announced positive results from a randomized, double-blind, Phase 2b, dose-ranging study of its formoterol fumarate metered dose inhaler (FF MDI; PT005), a long-acting beta-2 agonist (LABA) compared to placebo and Foradil® Aerolizer® in patients with moderate-to-severe COPD. All doses of FF MDI tested produced highly statistically significant improvements in lung function (FEV1 AUC 0-12) compared to...

LOS ANGELES, July 28, 2011 /PRNewswire/ -- UBM Canon has announced that it will produce the Pharmapack North America conference and exhibition May 22-23, 2012 in Philadelphia's PA Convention Center. The technology-focused conference and exhibition, which focuses upon innovation in packaging technology and drug delivery systems to enhance health product safety, is the counterpart of the company's highly successful show in Paris, France. (Logo:...

CANTON, Mass., July 26, 2011 /PRNewswire/ -- Armstrong Pharmaceuticals, Inc. announced the following news today concerning the future availability of Primatene® Mist: On December 31, 2011, the FDA ban on the sale of Primatene® Mist containing CFCs (chlorofluorocarbons) as a propellant will become effective. Primatene® Mist has proven to be a safe and effective treatment for asthma symptoms for over 40 years. The ban on the sale of Primatene® Mist is a result of the Montreal...

(Ivanhoe Newswire) -- People who use a mist inhaler to deliver a drug widely prescribed in more than 55 countries to treat chronic obstructive pulmonary disease (COPD) may be 52 percent more likely to die, according to this study.The findings raise concerns not only about the mist inhaler- a device that delivers a soluble form of the medication tiotropium- but also about the drug itself. The mist inhaler isn't approved in the U.S., but the drug in its powdered form is commonly used to treat...

REDWOOD CITY, Calif., June 16, 2011 /PRNewswire/ -- Pearl Therapeutics Inc. today announced the advancement of its dual combination product candidate, PT003 and its individual components, PT001 and PT005 into a series of planned Phase 2 studies in patients with moderate-to-severe COPD. PT003 (GFF MDI) is an investigational inhaled combination bronchodilator product comprising glycopyrrolate (GP), a long-acting muscarinic antagonist (LAMA), and formoterol (FF), a well-known, established,...

According to new study, Respimat, a mist inhaler that delivers a widely-prescribed respiratory drug, increases the risk of dying by half. The British and U.S. researchers looked at five trials involving Respimat, which can be alternatively taken in powder form. The drug Respimat uses tiotropium bromide, which relaxes muscles in the airways.  It is designed to ease symptoms of chronic obstructive respiratory disease (COPD), the world's fourth leading cause of death. The study was an...

People who use a mist inhaler to deliver a drug widely prescribed in more than 55 countries to treat chronic obstructive pulmonary disease (COPD) may be 52 percent more likely to die, new Johns Hopkins-led research suggests.The findings, published by BMJ, the British Medical Journal, raise concerns not only about the mist inhaler "” a device that delivers the soluble form of the medication tiotropium "” but also about the drug itself. The mist inhaler has not yet gained regulatory...

LISBON, Portugal, June 14, 2011 /PRNewswire/ -- Hovione announced today the international filing of its latest patent covering a new, highly efficient dry powder inhaler (DPI), XCaps. XCaps fills a void in the pulmonary inhalation market, as a device which combines high efficiency in powder dispersion with ease of use. Lung fractions in excess of 70% have been achieved, from a device which only requires two steps to inhalation and which only has two components plus a...

REDWOOD CITY, Calif., May 18, 2011 /PRNewswire/ -- Pearl Therapeutics Inc. presented detailed efficacy and safety results today from the Company's phase 2b study of PT003 (GFF MDI) in patients with moderate-to-very severe COPD during a late-breaker poster session at the annual meeting of the American Thoracic Society (ATS). PT003 is a proprietary fixed-dose combination of glycopyrrolate (GP), a long-acting muscarinic antagonist (LAMA), and formoterol fumarate (FF), an established,...

Nicotine-free plastic inhalers may increase a smoker's chance of quitting, according to new research published online in the European Respiratory Journal.This study is the first to assess the effectiveness of using a nicotine-free inhaler to help stop smoking.The research, which was carried out by scientists at the Università di Catania in Italy, analyzed 120 people who were enrolled in a program to help them quit smoking.The participants were split into two groups, with one group...